Description

As economy develops and living standards improve, Chinese people’s dietary pattern changes, resulting in excess heat. Meanwhile, the drop in physical activities leads to the increased obesity rate. Other factors like the ageing population also play a role in the rapid increase of diabetes incidence in China.

View Full Report at: http://www.marketresearchreports.biz/analysis/289187

Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, was developed by Novo Nordisk in 2008 to treat diabetes. Liraglutide, a derivative attained by attaching a fatty acid molecule to GLP-1 molecule, can reduce the HbA1c level and weight of type 2 diabetes mellitus (T2DM) patients and improve the function of beta cells. Since it stimulates insulin secretion and inhibits glucagon secretion only when blood glucose levels are higher than normal, it shows negligible risk of hypoglycemia. On Jan. 25, 2010, liraglutide was approved by FDA to be used as the second-line drug alone or together with other oral antidiabetic drugs for the treatment of T2DM. In 2013, the sales value of liraglutide around the world exceeded USD 2 billion.

After entering China in Oct. 2011, liraglutide develops fast with annual sales value rising from less than CNY 0.5 million in 2011 to CNY 19.71 million in 2014 and CAGR reaching up to 246% during the period of 2011-2013. Currently, liraglutide market in China is monopolized by Novo Nordisk. Although liraglutide, as an imported drug, is priced relatively high in China, it still has good market prospects.

Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/289187

Readers can get at least the following information from this report:

market size of liraglutide in China
price of liraglutide in Chinese market
share of dosage forms of liraglutide in China
market outlook of liraglutide in China



The author suggests the following groups of people purchase this report:

manufacturers of anti-diabetic drugs
investors/ research institutions interested in Chinese medicine market
any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Content

1 Related Concepts of Liraglutide
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Liraglutide in China
2.1 Patent and Approval Status of Liraglutide in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Liraglutide in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

Browse all latest Articles of Market Research Reports
at:http://www.marketresearchreports.biz/articles

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients.
We are a one stop solution for all your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.

Browse Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz

Browse More PressRelease:
http://www.prweb.com/search.aspx?search-releases=marketresearchreports.biz

Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: [email protected]